Opinion|Videos|June 27, 2024
Breast Cancer Treatment: NCCN Guideline Updates and Optimism at ASCO 2024
William J. Gradishar, MD, provides an overview of the current breast cancer treatment landscape, highlights updates to the NCCN guidelines from 2023 to 2024, and expresses optimism for addressing unmet needs at ASCO 2024.
Advertisement
Episodes in this series
- What current trends are you seeing in the world of breast cancer?How has the treatment of breast cancer evolved in recent history?
- Coming into ASCO 2024, what would you consider to be the largest unmet needs in the treatment and management of breast cancer?
- Provide the key recommendations and updates made in the 2024 NCCN guidelines for breast cancer.
- What have recommendationsfor the treatment and management of breast cancer changed since 2023?
Advertisement
Related to this article
Although PMOS Awareness Month has ended, the conversation continues, with experts saying closing diagnostic and care gaps requires ongoing efforts.
Invivyd's VYD2311 shows superior safety and tolerability vs Comirnaty in the phase 3 LIBERTY trial, with no vaccine interference.
Survodutide achieved up to 13.1% weight loss vs 3.1% with placebo at 76 weeks in adults with obesity and T2D in the phase 3 SYNCHRONIZE-2 trial.
A rare case of soft-tissue sarcoma spreading to the heart shows how multimodal imaging guided diagnosis and care in a 36-year-old man.
Weekend catch-up sleep was associated with lower odds of overactive bladder and milder symptoms, with the benefit concentrated in the first 1.5 hours.
The triple agonist also lowered HbA1C by up to 1.6% over 80 weeks, with up to 40% of participants reaching normal levels.
A network meta-analysis found vibegron outperformed mirabegron and tolterodine on several OAB efficacy measures but had higher odds of adverse events.
A US modeling study found tirzepatide and semaglutide cost-effective for MASH, while resmetirom exceeded the $100,000/QALY threshold.
Advertisement
Advertisement
Trending on AJMC
1
Dual Agonist Survodutide Delivers Up to 13.1% Weight Loss in T2D
2
FDA Accepts Inhaled Treprostinil sNDA for IPF: 4 FAQs for Payers
3
CMS Finalizes Mandatory GLOBE Model to Test Lower Part B Drug Costs
4
Proposed Medicare Rate Cuts Draw AASM Opposition Ahead of Final Rule
5